98%
921
2 minutes
20
Catecholamine-induced cardiomyopathy secondary to paraganglioma is a rare and potentially reversible condition. However, the course of recovery post-resection remains variable and may be delayed despite biochemical cure. We present the case of a 47-year-old male with biopsy-confirmed extra-adrenal paraganglioma who developed acute decompensated heart failure due to catecholamine-induced cardiomyopathy (left ventricular ejection fraction (LVEF) 30-35%) and multiorgan dysfunction. Despite successful surgical resection, his LVEF remained reduced postoperatively, and he was discharged on heart failure therapy and a wearable cardioverter defibrillator. A follow-up echocardiogram showed improvement in LVEF to 45% 2 weeks later, but his blood pressure remained poorly controlled despite adherence to a multi-drug regimen and lifestyle measures. He was readmitted with a transient ischemic attack (TIA) shortly after surgery. This case illustrates the variable recovery trajectory in paraganglioma-induced cardiomyopathy and highlights persistent cardiovascular risks, including resistant hypertension and cerebrovascular events despite biochemical cure. It emphasizes the importance of ongoing cardiac surveillance and multidisciplinary management, particularly in patients facing socioeconomic barriers to follow-up care.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12404122 | PMC |
http://dx.doi.org/10.14740/jmc5166 | DOI Listing |
J Med Cases
August 2025
Department of Cardiology, McLaren Health Care/Michigan State University, Flint, MI, USA.
Catecholamine-induced cardiomyopathy secondary to paraganglioma is a rare and potentially reversible condition. However, the course of recovery post-resection remains variable and may be delayed despite biochemical cure. We present the case of a 47-year-old male with biopsy-confirmed extra-adrenal paraganglioma who developed acute decompensated heart failure due to catecholamine-induced cardiomyopathy (left ventricular ejection fraction (LVEF) 30-35%) and multiorgan dysfunction.
View Article and Find Full Text PDFJACC Case Rep
August 2025
Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Background: Although exceedingly rare, pheochromocytomas can present with heart failure and cardiogenic shock, leading to complex management considerations.
Case Summary: A 49-year-old woman presented with chest pain and palpitations, and ultimately developed cardiogenic shock secondary to a pheochromocytoma. She required Impella 5.
Cureus
June 2025
Geriatric Medicine, Countess of Chester Hospital, Chester, GBR.
Pheochromocytoma is a neuroendocrine tumor of the adrenal gland. It can cause a range of symptoms, but the main ones are palpitations, pallor, headaches, and sweating. Due to its rarity and episodic character, it is frequently misdiagnosed in the initial instance.
View Article and Find Full Text PDFESC Heart Fail
July 2025
Department of Anaesthesiology and Intensive Care Medicine, Campus Charité Mitte and Campus Virchow-Klinikum, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Front Oncol
June 2025
Urology & Nephrology Center, Department of Urology, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China.
Pheochromocytomas are rare neuroendocrine tumors that can cause life-threatening cardiovascular complications due to excessive catecholamine secretion. One such severe manifestation is Takotsubo syndrome (TS), a catecholamine-induced cardiomyopathy that exacerbates hemodynamic instability. The coexistence of a giant pheochromocytoma and TS is extremely rare and presents formidable diagnostic and therapeutic challenges.
View Article and Find Full Text PDF